References
- Plunkett W., Huang P., Xu Y., Heinemann V., Grunewald R., Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol. 1995; 22: 3–10
- Guchelaar H., Richel D., Knapen A. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat. Rev. 1996; 22: 15–31
- Hanauske A., Degen D., Marshall M., Hilsenbeck S., Grindley G., Von H. Activity of 2′2′-difluorodeoxycytidine (gemcitabine) against human tumor colony forming units. Anticancer Drugs 1992; 4: 143–146
- Clinical Investigator's Brochure, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, 1995.
- Burkes R., Shepherd F. Gemcitabine in the treatment of non-small cell lung cancer. Ann. Oncol. 1995; 3(Suppl. 6)57–60
- Docetaxel Investigator's Brochure, V5.0, Rhone-Poulenc Rorer. Collegeville, PA, 1997.
- Bruno R., Sanderink G. Pharmacokinetics and metabolism of taxotere (docetaxel). Cancer Survey 1993; 17: 305–313
- Tomiak E., Piccart M., Kerger J., Lips S., Awada A., de Valeriola D. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J. Clin. Oncol. 1994; 12(7)1458–1467
- Aapro M. Docetaxel (taxotere): a highly active taxoid with manageable toxicity. Semin. Oncol. 1995; 22(Suppl. 4)1–2
- Burris H., Irvin R., Kuhn J. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J. Clin. Oncol. 1993; 11: 950–958
- Bissett D., Setanoians A., Cassidy J. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res. 1993; 53: 523–527
- Ratain M. Telephone interview: phase I clinical trial methodology. Clinical pharmacology. University of Chicago. 1999
- Georgoulias V., Kouroussis C., Androulakis N., Kakolyris S., Dimopoulos M., Papadakis E., Bouros D., Apostolopoulou F., Agelidou A., Hatzakis K., Kalbakis K., Kotsakis A., Vardakis N., Vlachonicolis J. Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J. Clin. Oncol. 1999; 17(3)914–920
- Quantin, X.; Tranchand, B.; Pujol, J.; Ardiet, C.; Khial, F.; Schuller, M.; Rebattu, P. Phase I and pharmacokinetic study of docetaxel (DTX) and gemcitabine (G) in patients with non-small cell lung cancer (NSCLC). Program/Proceedings ASCO, 1999.
- Gonzalo, R.,;Cesar, B.; Capo, A.; Eduardo, C.; Reinaldo, C.; Freue, M. Docetaxel and gemcitabine in metastatic non-small cell lung cancer (NSCLC): a phase II study. preliminary feasibility report. Program/Proceedings ASCO, 1999.